Literature DB >> 11527953

Inhibitory effect of ischemic preconditioning on leukocyte participation in retinal ischemia-reperfusion injury.

A Nonaka1, J Kiryu, A Tsujikawa, K Yamashiro, K Nishijima, K Miyamoto, H Nishiwaki, Y Honda, Y Ogura.   

Abstract

PURPOSE: Recent reports have shown that ischemic preconditioning induces strong protection against retinal damage by subsequent prolonged ischemia and that this protection is mediated by mechanisms involving the adenosine A1 receptor. This study was designed to evaluate quantitatively the effects of ischemic preconditioning on leukocyte-mediated reperfusion injury after transient retinal ischemia and to define the role of the adenosine A1 receptor in these effects.
METHODS: Transient retinal ischemia was induced in male rats by temporary ligation of the optic nerve. Ischemic preconditioning (5 minutes of ischemia) was induced 24 hours before 60 minutes of ischemia. The adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX) was administered intramuscularly immediately after ischemic preconditioning. Leukocyte behavior in the retina after 60 minutes of ischemia was evaluated in vivo with acridine orange digital fluorography.
RESULTS: Ischemic preconditioning inhibited leukocyte rolling. The maximum number of rolling leukocytes was reduced to 3.0% at 12 hours after reperfusion (P < 0.01). Subsequent leukocyte accumulation was also decreased with ischemic preconditioning. The maximum number of accumulated leukocytes was reduced to 22.6% at 24 hours after reperfusion (P < 0.01). These inhibitory effects were suppressed by administration of DPCPX (P < 0.0001). The numbers of rolling leukocytes at 12 hours after reperfusion and accumulated leukocytes at 24 hours after reperfusion were 102.7% (NS) and 83.4% (P < 0.01), respectively, compared with the number without ischemic preconditioning.
CONCLUSIONS: The present study demonstrates the inhibitory effects of ischemic preconditioning on leukocyte rolling and subsequent leukocyte accumulation during retinal ischemia-reperfusion injury. Furthermore, the adenosine A1 receptor may play an important role in these inhibitory effects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11527953

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  7 in total

1.  Mitochondrial potassium ATP channels and retinal ischemic preconditioning.

Authors:  Steven Roth; John C Dreixler; Afzhal R Shaikh; Katherine H Lee; Vytautus Bindokas
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

2.  Adaptive Plasticity in the Retina: Protection Against Acute Injury and Neurodegenerative Disease by Conditioning Stimuli.

Authors:  Jeffrey M Gidday
Journal:  Cond Med       Date:  2018-02-15

3.  Post-ischemic conditioning in the rat retina is dependent upon ischemia duration and is not additive with ischemic pre-conditioning.

Authors:  John C Dreixler; Afzhal R Shaikh; Michael Alexander; Brian Savoie; Steven Roth
Journal:  Exp Eye Res       Date:  2010-06-23       Impact factor: 3.467

4.  Ischemic preconditioning attenuates acute lung injury after partial liver transplantation.

Authors:  Qinlong Liu; Hasibur Rehman; Yasodha Krishnasamy; John J Lemasters; Zhi Zhong
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-04-20

5.  Transfer of lens-specific transcripts to retinal RNA samples may underlie observed changes in crystallin-gene transcript levels after ischemia.

Authors:  Willem Kamphuis; Frederike Dijk; Willem Kraan; Arthur A B Bergen
Journal:  Mol Vis       Date:  2007-02-08       Impact factor: 2.367

6.  Deferroxamine preconditioning promotes long-lasting retinal ischemic tolerance.

Authors:  Yanli Zhu; Lihong Zhang; Jeffrey M Gidday
Journal:  J Ocul Pharmacol Ther       Date:  2008-12       Impact factor: 2.671

7.  Global gene expression profiling of ischemic preconditioning in the rat retina.

Authors:  W Kamphuis; F Dijk; S van Soest; A A B Bergen
Journal:  Mol Vis       Date:  2007-06-28       Impact factor: 2.367

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.